ReviewDrugs2006
Irritable bowel syndrome: recent and novel therapeutic approaches.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 77 citations in OpenAlex.
- Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?American journal of physiology. Gastrointestinal and liver physiology · 2009Trial
- Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2007Trial
- How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial.Gastroenterology · 2007Trial
- Comparison of the Effects of pH-Dependent Peppermint Oil and Synbiotic Lactol (Bacillus coagulans + Fructooligosaccharides) on Childhood Functional Abdominal Pain: A Randomized Placebo-Controlled Study.Iranian Red Crescent medical journal · 2015Article
- An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa.Current neuropharmacology · 2015Review
- 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders.Frontiers in behavioral neuroscience · 2014Review
- Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome.Chinese journal of integrative medicine · 2012Article
- Prevalence of restless legs syndrome in patients with irritable bowel syndrome.World journal of gastroenterology · 2011Article
- The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome.Digestive diseases and sciences · 2009Article
- Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome.World journal of gastroenterology · 2009Article
- Review
- Changes in salivary physiological stress markers induced by muscle stretching in patients with irritable bowel syndrome.BioPsychoSocial medicine · 2008Article
- Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.Neurogastroenterology and motility · 2008Review
- Review
- Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor.Blood · 2007Article
- Tales from the crypts: regulatory peptides and cytokines in gastrointestinal homeostasis and disease.The Journal of clinical investigation · 2007Review
- Irritable bowel syndrome.Clinical drug investigation · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3-15% of the general population in Western countries. It is characterised by unexplained abdominal pain, discomfort and bloating in association with altered bowel habits. The pathophysiology of IBS is considered to be multifactorial, involving disturbances of the brain-gut-axis: IBS has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction and mucosal inflammation. Traditional IBS therapy is mainly symptom oriented and often unsatisfactory. Hence, there is a need for new treatment strategies. Increasing knowledge of brain-gut physiology, mechanisms, and neurotransmitters and receptors involved in gastrointestinal motor and sensory function have led to the development of several new therapeutic approaches. This article provides a systematic overview of recently approved or novel medications that show promise for the treatment of IBS; classification is based on the physiological systems targeted by the medication. The article includes agents acting on the serotonin receptor or serotonin transporter system, novel selective anticholinergics, alpha-adrenergic agonists, opioid agents, cholecystokinin antagonists, neurokinin antagonists, somatostatin receptor agonists, neurotrophin-3, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin and atypical benzodiazepines. Finally, the role of probiotics and antibacterials in the treatment of IBS is summarised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.